Blood clues may unlock mystery of brittle bone disease severity
NCT ID NCT04009733
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looked at 66 adults with Osteogenesis Imperfecta (brittle bone disease) to see if small molecules called microRNAs in the blood are linked to how severe the condition is. Researchers compared people with mild (type 1) and severe (type 3) forms, plus healthy controls. The goal was to find patterns that could explain why the same genetic mutation leads to very different outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help identify biological markers that predict disease severity, potentially guiding future treatments.
What could go wrong
This is an observational study, not a treatment trial. It is small (66 participants) and only looks at correlations, not causes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOGENESIS IMPERFECTA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Edouard Herriot
Lyon, 69003, France